MedTrace Logo

A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia During Pregnancy

NCT05803200 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2023-09-25

No results posted yet for this study

Summary

The main aim of this study is to provide further information on the safety profile of HyQvia during pregnancy. This will be done by checking the characteristics of the mother and their babies. They will also be checked for any safety outcomes that will occur when exposed to HyQvia during pregnancy.

Conditions

  • Exposure During Pregnancy

Interventions

DRUG

No intervention

No intervention was given as this is an observational study.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
16 Years
Max Age
44 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2023-04-14
Completion
2023-04-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05803200 on ClinicalTrials.gov